Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Cyclothiazide: Difference between pages
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 477110881 of page Cyclothiazide for the Chem/Drugbox validation project (updated: 'ChemSpiderID', 'DrugBank', 'ChEMBL', 'StdInChI', 'StdInChIKey'). |
Citation bot (talk | contribs) Alter: pages. | Use this bot. Report bugs. | Suggested by Boghog | #UCB_webform |
||
Line 1: | Line 1: | ||
{{short description|Chemical compound}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Cyclothiazide|oldid=477110881}} 477110881] of page [[Cyclothiazide]] with values updated to verified values.}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 477166277 |
||
| IUPAC_name = 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2''H''-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide |
| IUPAC_name = 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2''H''-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide |
||
| image = Cyclothiazide.png |
| image = Cyclothiazide.png |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
Line 11: | Line 10: | ||
| legal_status = Rx-only |
| legal_status = Rx-only |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| bioavailability = |
| bioavailability = |
||
Line 17: | Line 15: | ||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| IUPHAR_ligand = 4167 |
|||
| CASNo_Ref = {{cascite|correct|CAS}} |
|||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 2259-96-3 |
| CAS_number = 2259-96-3 |
||
Line 26: | Line 23: | ||
| PubChem = 2910 |
| PubChem = 2910 |
||
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} |
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} |
||
| DrugBank = |
| DrugBank = DB00606 |
||
| ChemSpiderID_Ref = {{chemspidercite| |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = 4535011 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = P71U09G5BW |
| UNII = P71U09G5BW |
||
Line 34: | Line 31: | ||
| KEGG = D01256 |
| KEGG = D01256 |
||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
||
| ChEMBL = |
| ChEMBL = 61593 |
||
<!--Chemical data--> |
|||
| C=14 | H=16 | Cl=1 | N=3 | O=4 | S=2 |
| C=14 | H=16 | Cl=1 | N=3 | O=4 | S=2 |
||
| molecular_weight = 389.88 g/mol |
|||
| smiles = O=S(=O)(c1c(Cl)cc2c(c1)S(=O)(=O)NC(N2)C4[C@@H]3\C=C/[C@@H](C3)C4)N |
| smiles = O=S(=O)(c1c(Cl)cc2c(c1)S(=O)(=O)NC(N2)C4[C@@H]3\C=C/[C@@H](C3)C4)N |
||
⚫ | |||
| |
| StdInChI = 1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)/t7-,8+,9?,14?/m0/s1 |
||
⚫ | |||
| |
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
||
⚫ | |||
| StdInChI = 1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)/t7-,8-,9?,14?/m1/s1 |
|||
⚫ | |||
| StdInChIKey = BOCUKUHCLICSIY-IHGGMMSTSA-N |
|||
}} |
}} |
||
'''Cyclothiazide''' ('''Anhydron''', '''Acquirel''', '''Doburil''', '''Fluidil''', '''Renazide''', '''Tensodiural''', '''Valmiran'''), sometimes abbreviated '''CTZ''', is a [[benzothiadiazide]] ([[thiazide]]) [[diuretic]] and [[antihypertensive]] that was originally introduced in the United States in 1963 by [[Eli Lilly and Company|Eli Lilly]] and was subsequently also marketed in [[Europe]] and [[Japan]].<ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000 | pages = 1932 | isbn = 978-3-88763-075-1 | url = https://books.google.com/books?id=5GpcTQD_L2oC&q=Cyclothiazide&pg=PA287}}</ref><ref name="isbn0-8155-1144-2">{{cite book | vauthors = Sittig M | title = Pharmaceutical manufacturing encyclopedia | publisher = Noyes Publications | location = Park Ridge, N.J., U.S.A | year = 1988 | pages = 1756 | isbn = 978-0-8155-1144-1 | url = https://books.google.com/books?id=X2EyLsG4bcUC&q=Cyclothiazide&pg=PA418}}</ref> Related [[drug]]s include [[diazoxide]], [[hydrochlorothiazide]], and [[chlorothiazide]].<ref name="isbn0-8493-8307-2">{{cite book | vauthors = Skolnick P, Palfreyman MG, Reynolds IJ | title = Direct and allosteric control of glutamate receptors | publisher = CRC Press | location = Boca Raton | year = 1994 | pages = 174 | isbn = 978-0-8493-8307-6 | url = https://books.google.com/books?id=Fp9RLJTt7NkC&q=Cyclothiazide&pg=PA65}}</ref> |
|||
In 1993, it was discovered that cyclothiazide is a [[positive allosteric modulator]] of the [[AMPA receptor|AMPA]] and [[kainate receptor]]s, capable of reducing or essentially eliminating rapid [[desensitization (medicine)|desensitization]] of the former receptor, and potentiating AMPA-mediated [[glutamate]] currents by as much as 18-fold at the highest concentration tested (100 [[micromolar|μM]]).<ref name="isbn0-8493-8307-2"/><ref name="pmid8103555">{{cite journal | vauthors = Yamada KA, Tang CM | title = Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents | journal = The Journal of Neuroscience | volume = 13 | issue = 9 | pages = 3904–3915 | date = September 1993 | pmid = 8103555 | pmc = 6576449 | doi = 10.1523/JNEUROSCI.13-09-03904.1993 | doi-access = free }}</ref><ref name="pmid7915948">{{cite journal | vauthors = Bertolino M, Baraldi M, Parenti C, Braghiroli D, DiBella M, Vicini S, Costa E | title = Modulation of AMPA/kainate receptors by analogues of diazoxide and cyclothiazide in thin slices of rat hippocampus | journal = Receptors & Channels | volume = 1 | issue = 4 | pages = 267–278 | year = 1993 | pmid = 7915948 }}</ref><ref name="isbn3-540-22568-4">{{cite book | vauthors = Parsons CG, Danysz W, Zieglgänsberger W | chapter = Excitatory Amino Acid Neurotransmission | veditors = Ströhle A, Bilkei-Gorzo A, Holsboer F | title = Anxiety and anxiolytic drugs | publisher = Springer | location = Berlin | year = 2005 | pages = 566 | isbn = 978-3-540-22568-3 | chapter-url = https://books.google.com/books?id=RDP4_sBnsl4C&q=Cyclothiazide&pg=PA256}}</ref> Additionally, in 2003, cyclothiazide was also found to act as a [[GABAA receptor|GABA<sub>A</sub> receptor]] [[negative allosteric modulator]], potently inhibiting GABA<sub>A</sub>-mediated currents.<ref name="pmid14534329">{{cite journal | vauthors = Deng L, Chen G | title = Cyclothiazide potently inhibits gamma-aminobutyric acid type A receptors in addition to enhancing glutamate responses | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 100 | issue = 22 | pages = 13025–13029 | date = October 2003 | pmid = 14534329 | pmc = 240738 | doi = 10.1073/pnas.2133370100 | doi-access = free | bibcode = 2003PNAS..10013025D }}</ref> In animals it is a powerful [[convulsant]], robustly enhancing [[epileptiform]] activity and inducing [[seizure]]s, but without producing any apparent [[neurotoxicity|neuronal death]].<ref name="pmid16423850">{{cite journal | vauthors = Qi J, Wang Y, Jiang M, Warren P, Chen G | title = Cyclothiazide induces robust epileptiform activity in rat hippocampal neurons both in vitro and in vivo | journal = The Journal of Physiology | volume = 571 | issue = Pt 3 | pages = 605–618 | date = March 2006 | pmid = 16423850 | pmc = 1805799 | doi = 10.1113/jphysiol.2005.103812 }}</ref><ref name="pmid20678492">{{cite journal | vauthors = Kong S, Qian B, Liu J, Fan M, Chen G, Wang Y | title = Cyclothiazide induces seizure behavior in freely moving rats | journal = Brain Research | volume = 1355 | pages = 207–213 | date = October 2010 | pmid = 20678492 | pmc = 2947190 | doi = 10.1016/j.brainres.2010.07.088 }}</ref> |
|||
Cyclothiazide has been found to act as a [[non-competitive antagonist]] of the [[mGluR1]].<ref name="pmid17095021">{{cite journal | vauthors = Surin A, Pshenichkin S, Grajkowska E, Surina E, Wroblewski JT | title = Cyclothiazide selectively inhibits mGluR1 receptors interacting with a common allosteric site for non-competitive antagonists | journal = Neuropharmacology | volume = 52 | issue = 3 | pages = 744–754 | date = March 2007 | pmid = 17095021 | pmc = 1876747 | doi = 10.1016/j.neuropharm.2006.09.018 }}</ref> It is selective for mGluR1 over other [[metabotropic glutamate receptor]]s.<ref name="pmid17095021" /> |
|||
==Synthesis== |
|||
[[File:Cyclothiazide synthesis.svg|thumb|center|700px|Cyclothiazide synthesis:<ref>{{Cite journal | doi = 10.1021/jo01066a046| title = Diuretics. V. 3,4-Dihydro-1,2,4-benzothiadiazine 1,1-Dioxides| journal = The Journal of Organic Chemistry| volume = 26| issue = 8| pages = 2814–2818| year = 1961| vauthors = Whitehead CW, Traverso JJ, Sullivan HR, Marshall FJ }}</ref><ref>{{cite patent | inventor = Müller E, Hasspacher K | country = US | number = 3275625 | gdate = 1966 | assign1 = [[Boehringer Ingelheim]] }}</ref>]] |
|||
== See also == |
|||
* [[AMPA receptor positive allosteric modulator]] |
|||
== References == |
|||
{{reflist}} |
|||
{{Diuretics}} |
|||
{{Navboxes |
|||
| title = [[Pharmacodynamics]] |
|||
| titlestyle = background:#ccccff |
|||
| list1 = |
|||
{{GABAA receptor modulators}} |
|||
{{Glutamate receptor modulators}} |
|||
}} |
|||
[[Category:Diuretics]] |
|||
[[Category:Sulfonamides]] |
|||
[[Category:AMPA receptor positive allosteric modulators]] |
|||
[[Category:Kainate receptor agonists]] |
|||
[[Category:Benzothiadiazines]] |
|||
[[Category:Chloroarenes]] |
|||
[[Category:GABAA receptor negative allosteric modulators]] |
|||
[[Category:Carbonic anhydrase inhibitors]] |
|||
[[Category:Convulsants]] |
|||
[[Category:MGlu1 receptor antagonists]] |
|||
[[Category:Alkene derivatives]] |